Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in
 symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
Inclusion Criteria:

 -  Diagnosis of COPD with symptoms over 1 year

 -  FEV1/FVC < 70% and FEV1 >= 30 and < 80 % of predicted post-bronchodilator

 -  Symptomatic COPD for a total of 7 days in the two weeks prior to randomisation

 -  At least 1 COPD exacerbation from 4 weeks to 12 months before the screening visit

 Exclusion Criteria:

 -  Past history or current evidence of clinically significant heart disease

 -  Current diagnosis of asthma

 -  Patients who require long term oxygen therapy

 -  Worsening of COPD requiring treatment with antibiotics, an increase in inhaled steroid
 dose and/or oral steroids within 4 weeks of study visit 1b